Home » Stocks » Exagen

Exagen Inc. (XGN)

Stock Price: $14.70 USD 0.05 (0.34%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 185.81M
Revenue (ttm) 39.19M
Net Income (ttm) -15.48M
Shares Out 12.64M
EPS (ttm) -72.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $14.70
Previous Close $14.65
Change ($) 0.05
Change (%) 0.34%
Day's Open 14.77
Day's Range 14.59 - 15.25
Day's Volume 3,716
52-Week Range 10.29 - 29.86

More Stats

Market Cap 185.81M
Enterprise Value 148.36M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 12.64M
Float 4.94M
EPS (basic) 28.24
EPS (diluted) -72.27
FCF / Share -1.10
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 140,768
Short Ratio 5.14
Short % of Float 2.85%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.74
PB Ratio 3.81
Revenue 39.19M
Operating Income -13.65M
Net Income -15.48M
Free Cash Flow -13.92M
Net Cash 37.45M
Net Cash / Share 2.96
Gross Margin 55.07%
Operating Margin -34.84%
Profit Margin -75.10%
FCF Margin -35.51%
ROA -14.80%
ROE -64.25%
ROIC -42.40%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(24.69% upside)
Current: $14.70
Target: 18.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth24.5%21.01%-
Gross Profit21.5817.0612.67
Operating Income-9.30-4.88-7.89
Net Income-12.04-8.01-25.63
Shares Outstanding3.580.060.06
Earnings Per Share-8.46-293.34-520.18
Operating Cash Flow-9.71-9.30-10.97
Capital Expenditures-0.10-0.20-0.51
Free Cash Flow-9.81-9.50-11.48
Cash & Equivalents72.0813.1611.24
Total Debt25.8524.6218.81
Net Cash / Debt46.23-11.45-7.57
Book Value55.66-112-96.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Exagen Inc.
Country United States
Employees 153
CEO Fortunato Ron Rocca

Stock Information

Ticker Symbol XGN
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: XGN
IPO Date September 19, 2019


Exagen develops and commercializes various testing products based on its Cell-Bound Complement Activation Products technology under the AVISE brand in the United States. It enable rheumatologists to enhance care for patients through the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company's products also comprise AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of eight autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a ten-biomarker panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease requiring aggressive therapy, such as anti-TNF biologics; and AVISE PC4d that measures platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a six-biomarker blood test; AVISE MTX, a patented and validated blood test that measures levels of MTXPG; and AVISE HCQ, a blood test designed to help rheumatologists objectively monitor levels of hydroxychloroquine. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.